173 related articles for article (PubMed ID: 35092262)
1. CLINICAL CASE OF NEUROMYELITIS OPTICA SPECTRUM DISORDERS IN YOUNG WOMAN TREATED WITH RITUXIMAB.
Poiasnyk IM; Gryb VA
Wiad Lek; 2022; 75(1):132-137. PubMed ID: 35092262
[TBL] [Abstract][Full Text] [Related]
2. Gaze palsy, hypogeusia and a probable association with miscarriage of pregnancy--the expanding clinical spectrum of non-opticospinal neuromyelitis optica spectrum disorders: a case report.
Chang T; Withana M
BMC Res Notes; 2015 Feb; 8():36. PubMed ID: 25888897
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorder with increased aquaporin-4 microparticles prior to autoantibodies in cerebrospinal fluid: a case report.
Bejerot S; Hesselmark E; Mobarrez F; Wallén H; Hietala MA; Nybom R; Wetterberg L
J Med Case Rep; 2019 Jan; 13(1):27. PubMed ID: 30696485
[TBL] [Abstract][Full Text] [Related]
4. Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab.
Shidahara K; Hayashi K; Sada KE; Hiramatsu S; Morishita M; Watanabe H; Matsumoto Y; Kawabata T; Wada J
Lupus; 2018 Jul; 27(8):1374-1377. PubMed ID: 29498304
[TBL] [Abstract][Full Text] [Related]
5. Spectrum disorder of neuromyelitis optica in a patient presenting with intractable vomiting and hiccups, transverse myelitis and acute encephalopathy.
Patel V; Griffith NC; Blackwood E; Dias M; Cordato DJ
J Clin Neurosci; 2012 Nov; 19(11):1576-8. PubMed ID: 22925418
[TBL] [Abstract][Full Text] [Related]
6. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis Optica (Devic's Syndrome): an Appraisal.
Crout TM; Parks LP; Majithia V
Curr Rheumatol Rep; 2016 Aug; 18(8):54. PubMed ID: 27402111
[TBL] [Abstract][Full Text] [Related]
8. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
[TBL] [Abstract][Full Text] [Related]
10. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
Yaguchi H; Sakushima K; Takahashi I; Nishimura H; Yashima-Yamada M; Nakamura M; Tsuzaka K; Maruo Y; Takahashi T; Yabe I; Sasaki H
Intern Med; 2013; 52(9):969-72. PubMed ID: 23648715
[TBL] [Abstract][Full Text] [Related]
12. Neuromyelitis optica with brain stem involvement in a middle-aged Ethiopian woman: a case report and review of literature.
Kassu RA; Mulatu HA; Gizaw S; Fisseha H; Musema A; Keder A; Negash S; Tefera F; Lissanwerk A; Tamrat L
J Med Case Rep; 2021 Oct; 15(1):489. PubMed ID: 34598735
[TBL] [Abstract][Full Text] [Related]
13. Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancy.
Munger KC; Samkoff LM
Mult Scler Relat Disord; 2020 Jan; 37():101442. PubMed ID: 32173005
[TBL] [Abstract][Full Text] [Related]
14. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
[TBL] [Abstract][Full Text] [Related]
15. Pediatric familial neuromyelitis optica in two sisters with long term follow-up.
Chuquilin M; Mullaguri N; Weinshenker B
J Clin Neurosci; 2016 Jul; 29():183-4. PubMed ID: 26898580
[TBL] [Abstract][Full Text] [Related]
16. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease.
Magaña SM; Pittock SJ; Lennon VA; Keegan BM; Weinshenker BG; Lucchinetti CF
Arch Neurol; 2009 Aug; 66(8):964-6. PubMed ID: 19667216
[TBL] [Abstract][Full Text] [Related]
17. Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder from Ethiopia: A Case Report.
Melka D
Ethiop J Health Sci; 2020 Sep; 30(5):847-852. PubMed ID: 33911847
[TBL] [Abstract][Full Text] [Related]
18. [A case of neuromyelitis optica spectrum disorders associated with primary biliary cholangitis: a twelve year follow-up study].
Sakai T; Kondo M; Kawana Y; Inoue R
Rinsho Shinkeigaku; 2022 Mar; 62(3):190-197. PubMed ID: 35228461
[TBL] [Abstract][Full Text] [Related]
19. Recurrent spinal cord attacks in a patient with a limited form of neuromyelitis optica.
Matsumoto H; Shimizu T; Okabe S; Konoma Y; Takahashi T; Hirakawa-Yamada M; Igeta Y; Hashida H
Intern Med; 2011; 50(5):509-13. PubMed ID: 21372469
[TBL] [Abstract][Full Text] [Related]
20. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
